neuromuscular disorder
Novartis Acquires Kate Therapeutics in $1.1B Deal
The acquisition is poised to strengthen Novartis' position in the gene therapy market for neuromuscular conditions.
Lexeo Therapeutics to Dose First Human in Arrhythmogenic Cardiomyopathy Gene Therapy Trial
The firm will dose the first patient in the trial of LX2020 in the first half of 2024, the CEO said at the JP Morgan Healthcare Conference.
Solve GNE Raises $2.5M to Fund Gene Therapy Research at Johns Hopkins, Stanford, Biotech Firms
The nonprofit hopes its funds will help researchers quickly bring multiple gene therapy candidates for GNE myopathy to the FDA.
Lexeo Therapeutics Kicks Off Second Cohort in FA Cardiomyopathy Gene Therapy Trial
The gene therapy candidate, LX2006, delivers a functional FXN gene to treat Friedreich's ataxia cardiomyopathy.